Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
79%
Natural Killer Cells
61%
Confidence Interval
50%
Hematopoietic Cell Transplantation
46%
Overall Survival
45%
Acute Myeloid Leukemia
43%
Bone Marrow Transplantation
39%
Unrelated Donor
37%
Marrow Transplantation
35%
Breast Cancer
34%
Transplantation
34%
Chemotherapy
33%
Tumor
30%
Sickle Cell Disease
30%
Leukemia
29%
Chronic Myeloid Leukemia
28%
Insulin-like
27%
Hazard Ratio
25%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
23%
Bone Marrow
22%
Growth Factors
22%
Allogeneic Bone Marrow Transplantation
21%
Endothelial Cells
21%
Myelodysplastic Syndrome
21%
Clinical Trials
20%
Umbilical Cord Blood
19%
Marrow
19%
Prostate Cancer
19%
In Cancer
18%
Reduced-intensity Conditioning
18%
High Risk
17%
T Cells
17%
Acute Lymphoblastic Leukemia
17%
Risk Factors
17%
Progression-free Survival
16%
Hematological Malignancies
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Survivors
16%
Clinical Outcomes
16%
Phase II Trial
16%
Progesterone Receptor
16%
Granulocytes
16%
Breast Cancer Cells
15%
Non-Hodgkin Lymphoma
15%
Cyclophosphamide
15%
Umbilical Cord Blood Transplantation
15%
Phase II Study
14%
Hematopoietic Stem Cell Transplantation
14%
Lymphoma
14%
Hematopoietic Stem Cells
14%
Prednisone
13%
Acute Leukemia
13%
Complete Remission
13%
Non-relapse Mortality
13%
Remission
13%
Pretransplant
13%
Multiple Myeloma
12%
Endothelium
12%
Interleukin-2
12%
Disease-free Survival
12%
Gene Expression
11%
Inflammation
11%
Lymphocytes
11%
Human Embryonic Stem Cells (hESCs)
11%
Interleukin-15 (IL-15)
11%
Peripheral Blood
11%
Monoclonal Antibody
11%
Killer Cell Immunoglobulin-like Receptor
10%
United States
10%
Neutrophils
10%
Allogeneic Transplantation
10%
Insulin-like Growth Factor 1 Receptor (IGF1R)
10%
Transplant Outcomes
10%
Platelets
10%
Total Body Irradiation
10%
Allogeneic
9%
Cytotoxicity
9%
Sickle Cell Anemia
9%
Myeloablative
9%
Cancer Cells
9%
Relative Risk
9%
Unrelated Donor Transplantation
9%
Leukemia Patients
9%
Odds Ratio
9%
Malignancy
9%
Myeloablative Conditioning
9%
Hemophilia
9%
Relapsed or Refractory
9%
Phosphorylation
9%
Multivariate Analysis
9%
Engraftment
9%
Complete Response
8%
Heme
8%
First Complete Remission
8%
Cell Therapy
8%
Older Adults
8%
Lung Cancer
8%
University of Minnesota
8%
Cancer Treatment
8%
Medicine and Dentistry
Hematopoietic Cell
79%
Cell Transplantation
63%
Diseases
57%
Breast Cancer
53%
Malignant Neoplasm
52%
Neoplasm
44%
Overall Survival
42%
Acute Myeloid Leukemia
40%
Bone Marrow Transplantation
38%
Graft Versus Host Reaction
35%
Prostate Cancer
30%
Sickle-Cell Disease
29%
Chronic Graft Versus Host Disease
25%
Chronic Myelogenous Leukemia
24%
Natural Killer Cell
24%
Clinical Trial
24%
Leukemia
22%
Myelodysplastic Syndrome
21%
Hazard Ratio
20%
Endothelial Cell
19%
In Vitro
18%
Cord Blood
18%
Cancer
18%
Cancer Cell
18%
Acute Graft Versus Host Disease
17%
Infection
17%
T Cell
16%
Acute Lymphoblastic Leukemia
16%
Biological Marker
16%
Progression Free Survival
15%
Immunotherapy
14%
Metastatic Carcinoma
14%
Allograft
14%
Hematopoietic Stem Cell Transplantation
14%
Non Small Cell Lung Cancer
14%
Cancer Therapy
14%
Oncology
13%
Non-Hodgkin Lymphoma
13%
Receptor
12%
Hematologic Malignancy
12%
Cyclophosphamide
12%
Reduced Intensity Conditioning
12%
Disease Free Survival
11%
Castration Resistant Prostate Cancer
11%
Acute Leukemia
11%
Hodgkin's Lymphoma
11%
Conditioning
10%
Multiple Myeloma
10%
Platelet
10%
Quality of Life
10%
Erythrocyte
10%
Melanoma
10%
Allogenic Bone Marrow Transplantation
10%
Gene Expression
10%
Lung Cancer
10%
Whole Body Radiation
9%
Cell Therapy
9%
Granulocyte
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Lymphocyte
9%
Somatomedin
8%
Drug Megadose
8%
COVID-19
8%
Engraftment
8%
Lung
8%
Adverse Event
8%
Cord Blood Stem Cell Transplantation
7%
Infusion
7%
Odds Ratio
7%
Neutrophil
7%
Diffuse Large B-Cell Lymphoma
7%
B Cell
7%
Multivariate Analysis
7%
Ovarian Cancer
7%
Prognostic Factor
7%
Targeted Therapy
7%
Recurrent Disease
6%
Immunosuppressive Treatment
6%
Stem Cell
6%
Mast Cell
6%
Mesothelioma
6%
Doxorubicin
6%
Prevalence
6%
Radiation Therapy
6%
Cytokine
6%
Cardiovascular Disease
6%
Arm
6%
Survival Rate
6%
Health Care Cost
6%
Leukocyte
6%
Monoclonal Antibody
6%
Cell Activation
6%
Human Embryonic Stem Cell
5%
Interleukin 2
5%
Cytotoxicity
5%
Myeloablative Conditioning
5%
Messenger RNA
5%
Autotransplantation
5%
Androgen Receptor
5%
Cumulative Incidence
5%